Intelligence · Clinical Development
Pipeline search results
Programs matching “Celgene Europe” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 45 pipeline programs matching "Celgene Europe" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
CA061-1011
Celgene Europe Limited
Lupus Nephritis, Systemic Lupus Erythematosus
1 trial -
CA073-1022
Celgene Europe Limited
Newly Diagnosed Advanced Stage Follicular Lymphoma
1 trial -
CC-220-MM-001
Celgene Europe Limited
Multiple Myeloma
1 trial -
CC-486-NSCL-001
Celgene Europe Limited
Second-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC)
1 trial -
CC-92480-MM-001
Celgene Europe Limited
Relapsed and refractory multiple myeloma (RRMM)
1 trial -
CC-92480-MM-002
Celgene Europe Limited
Relapsed or refractory multiple myeloma (RRMM) and newly diagnosed MM (NDMM)
1 trial -
CC-99282-NHL-001
Celgene Europe Limited
Follicular B-cell non-Hodgkin's lymphoma, Primary central nervous system lymphoma, Marginal zone lymphoma, Diffuse large B-cell lymphoma, Mantle cell lymphoma
1 trial -
IM045-1018
Celgene Europe Limited
Multiple Sclerosis Spasticity
1 trial -
JCAR017
Celgene Europe Limited
Lymphoma, Non-Hodgkin
1 trial -
Lisocabtagene maraleucel
Celgene Europe Limited
Relapsed or refractory indolent B-cell Non-Hodgkin Lymphoma (NHL)
1 trial -
Pomalidomide
Celgene Europe Limited
Multiple Myeloma
1 trial -
idecabtagene vicleucel
Celgene Europe Limited
Relapsed and refractory multiple myeloma (RRMM), multiple myeloma (MM) with progression within 18 months of initial treatment/ or newly diagnosed multiple myeloma (NDMM) with suboptimal response post autologous stem cell transplant (ASCT) (Cohort 3 only)
1 trial -
CA059-001
Celgene Europe Limited
Acute Myeloid Leukemia and Myelodysplastic Syndromes
1 trial -
CA061-1001
Celgene Europe Limited
Systemic Sclerosis, Rheumatoid Arthritis (RA), Idiopathic Inflammatory Myopathy, Systemic Lupus Erythematosus (SLE)
1 trial -
CA061-1006
Celgene Europe Limited
Myasthenia gravis (MG), Progressive Multiple Sclerosis (PMS), Relapsing Multiple Sclerosis (RMS)
1 trial -
CA1190002
Celgene Europe Limited
Relapsed and/or Refractory Multiple Myeloma
1 trial -
CC-486
Celgene Europe Limited
Leukemia, Myeloid, Acute
1 trial -
CC-90010-GBM-002
Celgene Europe Limited
Subjects with newly diagnosed WHO Grade IV glioblastoma (ndGBM) who have undergone complete or partial tumor resection
1 trial -
CC-90010-ST-001
Celgene Europe Limited
Part C: advanced or unresectable STs (Spain only), Part B : r/r diffuse large B cell lymphoma (DLBCL) (Cohort 1), advanced basal cell carcinoma (BCC) (Cohort 2), r/r DLBCL under an alternative dosing regimen (Cohort 3), Part A: advanced or unresectable solid tumors (STs) and relapsed and/or refractory (r/r) advanced non-Hodgkin's lymphomas (NHLs)
1 trial -
CC-90011-SCLC-001
Celgene Europe Limited
extensive stage small cell lung cancer
1 trial -
pomalidomide
Celgene Europe Limited
Multiple Myeloma in Relapse
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.